Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.

about

Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases

P2860

Q33689314-0D64EA19-8CAF-41B4-B5A5-19FA0E4EECE9

P2860

Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.

Item

http://www.wikidata.org/entity/Q40634245

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Progression-free and overall s ...... ith serial C11-acetate PET/CT.

@en

type

Item

label

Progression-free and overall s ...... ith serial C11-acetate PET/CT.

@en

prefLabel

Progression-free and overall s ...... ith serial C11-acetate PET/CT.

@en

P1476

Progression-free and overall s ...... ith serial C11-acetate PET/CT.

@en

P2093

Agnes Wadelius

http://www.w3.org/2001/XMLSchema#string

Anders Ullén

http://www.w3.org/2001/XMLSchema#string

Hans Jacobsson

http://www.w3.org/2001/XMLSchema#string

Jacob Farnebo

http://www.w3.org/2001/XMLSchema#string

Lennart Blomqvist

http://www.w3.org/2001/XMLSchema#string

Per Sandström

http://www.w3.org/2001/XMLSchema#string

Sten Nilsson

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.

Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

PET imaging of prostate cancer using carbon-11-choline.

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.

(11)C-acetate PET/CT in pre-therapeutic lymph node staging in high-risk prostate cancer patients and its influence on disease management - a retrospective study.

Current and emerging therapies for bone metastatic castration-resistant prostate cancer.

P304

e4308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000004308

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27495034

http://www.w3.org/2001/XMLSchema#string

P932

4979788

http://www.w3.org/2001/XMLSchema#string

Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.

about

P2860

P2860

Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932